Account
Articles
15.02.2024
PATT 2.0: NICE Priorities & Pharma Impact

We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...

Read more
Insider Insights
14.02.2024
NICE update: What manufacturers need to know about...

Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
News
16.11.2023
ISPOR Europe 2023

We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...

Read more
Webinar
31.10.2023
NICE’s Proportionate Approach to Technology ...

Webinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...

Read more
Publications
25.10.2023
ISPOR Europe 2023: How Has NICE’s Severity M...

Our study aims to understand how the severity modifier has been implemented so far and its impact on...

Read more
Insider Insights
14.09.2023
AMR Subscription Model Consultation by NHS England

Learn about the ground breaking consultation by NHS England and NICE on expanding the Antimicrobial ...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
Insider Insights
04.05.2023
NICE collaborates with international partner agenc...

UK, Canada and United States join forces to streamline process and increase transparency for confide...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.